Catalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to “Hold” Rating by Zacks Research

Posted by Brenda Bartman on May 20th, 2026

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.17.

View Our Latest Analysis on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Trading Down 0.1%

Shares of CPRX stock opened at $31.21 on Monday. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56. The firm’s fifty day moving average price is $26.42 and its two-hundred day moving average price is $24.50. The firm has a market capitalization of $3.82 billion, a P/E ratio of 17.94, a PEG ratio of 0.91 and a beta of 0.72.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CPRX. Deerfield Management Company L.P. increased its position in Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares during the period. Janus Henderson Group PLC increased its position in Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after buying an additional 1,147,565 shares during the period. Morgan Stanley increased its position in Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after buying an additional 1,089,775 shares during the period. Bank of America Corp DE increased its position in Catalyst Pharmaceuticals by 38.0% during the 1st quarter. Bank of America Corp DE now owns 3,036,546 shares of the biopharmaceutical company’s stock worth $75,185,000 after buying an additional 836,704 shares during the period. Finally, American Century Companies Inc. increased its position in Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after buying an additional 770,198 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).